A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

DRUG

Insulin Glargine

Administered SC

Trial Locations (27)

101200

Beijing Pinggu District Hospital, Beijing

116033

Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian

130021

The First Hospital of Jilin University, Changchun

150001

First Affiliated Hospital of the Harbin Medical University, Harbin

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

200062

Shanghai Putuo District Center Hospital, Shanghai

210000

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

210012

The First Hospital of Nanjing, Nanjing

211100

Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing

213003

Changzhou No.2 People's Hospital, Changzhou

214023

Wuxi People's Hospital, Wuxi

214400

The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi

215004

No. 2 Affiliated Hospital of Suzhou University, Suzhou

230011

The Second People's Hospital of Hefei, Hefei

250013

Jinan Central Hospital, Jinan

300052

Tianjin Medical University General Hospital, Tianjin

310013

Zhejiang Hospital, Hangzhou

330009

The Third Hospital of Nanchang, Nanchang

337000

Pingxiang People's Hospital, Pingxiang

400014

Chongqing General Hospital, Chongqing

450014

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

471003

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

610041

West China Hospital Sichuan University, Chengdu

650034

The First People's Hospital of Yunnan Province, Kunming

710077

The First Affiliated Hospital of Xi'an Medical University, Xi’an

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04591626 - A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter